Class A Common Stock

Class A Common Stock

Reflects the conversion of Class A Common Units ("Class A Units") of Carvana Group, LLC ("Carvana Group") owned directly by Ernest C. Garcia II into shares of Class A Common Stock ("Class A Shares") of the Issuer pursuant to the Exchange Agreement, dated April 27, 2017, by and among the Issuer, Carvana Co. Sub LLC, Carvana Group and the members of Carvana Group (the "Exchange Agreement").

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ernest C. Garcia II and Elizabeth Joanne Garcia on December 13, 2024.

Prices reported in Column 4 are weighted average prices.  Shares sold in multiple transactions at prices ranging from $351.94-$352.8825, inclusive (weighted $352.6209); $352.94-$353.92, inclusive (weighted $353.5066); $353.95-$354.94, inclusive (weighted $354.444); $354.97-$355.96, inclusive (weighted $355.4391); $355.97-$356.92, inclusive (weighted $356.2653); $356.99-$357.88, inclusive (weighted $357.3966); $357.99-$358.93, inclusive (weighted $358.528); $358.995-$359.94, inclusive (weighted $359.4163); $360.02-$361.01, inclusive (weighted $360.6798); $361.02-$362.005, inclusive (weighted $361.5093); $362.02-$363.01, inclusive (weighted $362.4417); $363.05-$364.00, inclusive (weighted $363.5722); $364.07-$364.86, inclusive (weighted $364.3689); $365.29-$366.04, inclusive (weighted $365.6814); $366.45-$367.22, inclusive (weighted $366.8857); and $367.46-$367.88, inclusive (weighted $367.6728), respectively.

The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Reflects the cancellation for no consideration of Class B Common Stock of the Issuer ("Class B Shares") in connection with the conversion of Class A Units into Class A Shares. Following the reported transaction, the remaining Class B Shares are owned directly by Ernest C. Garcia II.

These Class B Shares are owned directly by ECG II SPE, LLC ("E-SPE"), an entity which Mr. Garcia wholly owns and controls.

These Class A Units are owned directly by E-SPE and are exchangeable for 0.8 Class A Shares pursuant to the Exchange Agreement.


Non-Qualified Stock Option (right-to-buy)

Common Stock

Common Stock

Common Stock

Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

Represents the weighted average price of the shares sold ranging from a low of $630.50 to a high of $630.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2018.

Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2019.

Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020.

/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt


Air Lease Corporation - Class A Common Stock

The price reported in Column 4 is the weighted average sales price. These shares were sold in multiple transactions at prices ranging from $55.410 to $55.440, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 1 to this Form 4.


The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $43.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Class A Common Stock

Class A Common Stock

The prices reported in Column 4 are weighted average prices.  These shares were sold in multiple transactions at prices ranging from $345.91-$346.895, inclusive (weighted average of $346.5768); $346.93-$347.92, inclusive (weighted average of $347.3647); $347.93-$348.91, inclusive (weighted average of $348.4878); $348.93-$349.91, inclusive (weighted average of $349.4392); $349.94-$350.935, inclusive (weighted average of $350.3552); $350.97-$351.87, inclusive (weighted average of $351.3454); $352.045-$353.00, inclusive (weighted average of $352.5815); $353.14-$354.12, inclusive (weighted average of $353.678); $354.17-$355.16, inclusive (weighted average of $354.7102); $355.17-$356.16, inclusive (weighted average of $355.58); $356.175-$357.095, inclusive (weighted average of $356.6267); and $357.275-$357.355, inclusive (weighted average of $357.3272), respectively.


Common Stock

Includes 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

Represents the weighted average price of the shares sold ranging from a low of $626.585 to a high of $627.44 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $627.72 to a high of $628.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $629.14 to a high of $630.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $630.14 to a high of $630.885 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $631.26 to a high of $632.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $632.41 to a high of $633.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $634.66 to a high of $635.64 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $635.66 to a high of $636.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $636.66 to a high of $637.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $639.235 to a high of 639.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Grant of option to buy 41,260 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2017.

Not applicable

/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky


Common Stock

Common Stock

Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

Represents the weighted average price of the shares sold ranging from a low of $626.70 to a high of $627.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $627.70 to a high of $628.62 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Represents the weighted average price of the shares sold ranging from a low of $628.82 to a high of $628.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

Grant of option to buy 8,366 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020.

Grant of option to buy 7,125 shares of Issuer common stock that became exercisable in four annual installments beginning February 14, 2021.

/s/ Lily J. Lu, Attorney-in-Fact for Michael Lane


These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 11, 2025.


These shares were awarded as part of the Company's compensation program for non-management directors in connection with the 2025 annual stockholders' meeting.


Reflects shares of the issuer's common stock withheld to cover the reporting person's tax liability in connection with the vesting of restricted stock units. This transaction was not an open market sale by the reporting person.

/s/ Zabi Nowaid, Attorney-in-Fact for Fred Thiel


The reporting person and his spouse are trustees of the S & N Khan Family Trust, and members of the reporting person's immediate family are the sole beneficiaries of the trust.

/s/ Zabi Nowaid, Attorney-in-Fact for Salman Khan


The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

/s/ Zabi Nowaid, Attorney-in-Fact for Douglas K. Mellinger


The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $28.04. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The share numbers in Column 5 represent the aggregated holdings of Abdiel Qualified Master Fund, LP ("AQMF"), Abdiel Capital, LP ("ACLP") and Abdiel Partners, LLC ("APLLC").  Abdiel Capital Advisors, LP serves as the investment manager of AQMF, ACLP and APLLC.  Abdiel Capital Management, LLC is the general partner of AQMF and ACLP. Colin T. Moran is the managing member of Abdiel Capital Management, LLC and Abdiel Capital Partners, LLC, which is the general partner of Abdiel Capital Advisors, LP and the managing member of APLLC. By virtue of the foregoing relationships, Mr. Moran and Abdiel Capital Advisers LP may be deemed to beneficially own the securities held by AQMF, ACLP and APLLC, and Abdiel Capital Management LLC may be deemed to beneficially own the securities held by AQMF and ACLP. Each Reporting Person disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.

The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.14 to $29.60. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $31.00. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.87. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.13 to $32.20. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported for the Common Stock is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.47. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025.

This transaction was executed in multiple trades during the day at prices ranging from $188.15 to $188.32. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $179.75 to $180.45. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $183.23 to $184.18. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $173.94 to $174.75. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $181.00 to $181.81. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $185.96 to $186.83. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $174.94 to $175.91. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $170.79 to $171.78. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $178.67 to $179.28. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $182.08 to $182.88. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Shares are held by CBC Co Pty Limited as trustee for the Cannon-Brookes Head Trust.

This transaction was executed in multiple trades during the day at prices ranging from $169.75 to $170.74. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $176.02 to $176.82. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $171.88 to $172.87. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $187.09 to $187.79. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $177.15 to $177.94. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $172.88 to $173.87. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Veena Bhatia, Attorney-in-Fact for Cannon-Brookes Michael


This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 12, 2025.

Shares are held by Farquhar Investment Partnership No. 2.

This transaction was executed in multiple trades during the day at prices ranging from $188.15 to $188.32. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $179.75 to $180.45. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

This transaction was executed in multiple trades during the day at prices ranging from $181.00 to $181.81. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Veena Bhatia, Attorney-in-Fact for Farquhar Scott


Common Stock

The sales were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The Reporting Person entered into the Rule 10b5-1 trading plan in connection with the expiration of certain stock options held by the Reporting Person and related sales of shares to satisfy the exercise price and tax withholding obligations upon the exercise of such stock options.

This transaction was executed in multiple trades at prices ranging from $236.41 to $237.38. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $237.42 to $238.36. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $238.41 to $239.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $239.48 to $239.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer or a security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Shares are held by the Siegel/Elsesser Revocable Trust.

All shares are vested and exercisable.

/s/ Stephen Dobson, as attorney-in-fact for Adam Elsesser


These represent deferred stock units ("DSU") that were awarded as part of the Company's compensation program for non-management directors in connection with the 2025 annual stockholders' meeting. Each DSU constitutes the right to receive one share of the Company's common stock upon settlement (which occurs when the recipient's service with the Company is concluded). During the remaining term of service, DSUs are nontransferable and carry neither voting nor dividend rights. DSUs are subject to the terms and conditions of the Company's standard form DSU agreement.


Represents shares of common stock withheld by the issuer to satisfy tax obligations in connection with the vesting of restricted stock granted to the Reporting Person pursuant to Rule 16b-3(d).


Vesting of Performance Stock for no cash consideration pursuant to the Twin Disc, Incorporated 2021 Long-Term Incentive Compensation Plan.

Represents shares of common stock withheld by the issuer to satisfy tax obligations in connection with the vesting of performance stock granted to the Reporting Person pursuant to Rule 16b-3(d).

Award of Restricted Stock for no cash consideration pursuant to the Twin Disc, Incorporated 2021 Omnibus Incentive Plan. Grant will vest 100% on 8/6/2028.


As trustee of Michael E. Batten Marital Trust.

As trustee of Michael E. Batten Family Trust.

As trustee of Elizabeth Batten Stribney Trust.

As trustee of Timothy Michael Batten Trust.

As trustee of Louise Vemet Batten Grantor Trust.


Reflects the acquisition by a trust for the benefit of certain of the Reporting Person's family members from certain of the Reporting Person's other family members of their limited liability company membership interests in a limited liability company holding shares of common stock of KKR & Co. Inc. The number reported reflects the number of shares held by the limited liability company that corresponds with the limited liability company membership interests transferred to the trust described above. In connection with the transfer to the trust described above, the trust paid the transferors an aggregate of $227,250.04.

These securities are held by a limited partnership, whose general partner is a limited liability company over which the Reporting Person has investment discretion.

Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended, the Reporting Person states that this filing shall not be an admission that the Reporting Person is the beneficial owner of any of the securities reported herein as indirectly owned, and the Reporting Person disclaims beneficial ownership of such securities except to the extent of the Reporting Person's pecuniary interest therein.


Common Stock

Vesting of Restricted Stock Units with performance conditions for no cash consideration pursuant to the Twin Disc, Incorporated 2021 Long-Term Incentive Compensation Plan.

Represents shares of common stock withheld by the issuer to satisfy tax obligations in connection with the vesting of Restricted Stock Units with performance conditions granted to the Reporting Person pursuant to Rule 16b-3(d).

Restricted Stock Units convert into common stock based on achievement of performance objectives.

On August 3, 2022, reporting person was granted 72,376 Restricted Stock Units with performance conditions, which vested at 166% of target based on the three-year period ending June 30, 2025.


This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski


The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Includes Restricted Stock Units that have not yet vested.


Common Stock

These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Includes: (i) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;

(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 96,000 RSUs granted on April 2, 2024 and of which 48,000 remain unvested as of the date hereof; and

(continued from footnote 3) (iv) 1,013,363 shares of Common Stock owned by the Reporting Person.

These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

/s/ Peter J. Mariani attorney-in-fact Phillip P. Chan


Common Stock

Includes: (i) the following Restricted Stock Units ("RSUs") that will be settled into Common Stock vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 19,534 shares of Common Stock owned by the reporting person.

The stock options were granted pursuant to the Plan. The shares underlying the stock options will vest in four (4) equal quarterly installments over a period of one year following the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

/s/ Peter J. Mariani attorney-in-fact Edward R. Jones


Common Stock

Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 81,973 shares of Common Stock owned by the Reporting Person.

/s/ Peter J. Mariani attorney-in-fact Michael G. Bator


Common Stock

Includes (a) 110,000 restricted stock units ("RSUs"), which will be settled into the Issuer's common stock, par value $0.001 per share (the "Common Stock"), upon vesting upon the earlier of (i) a "Change In Control" of the Issuer, as defined in the Reporting Person's employment agreement (the "Employment Agreement"), or (ii) the fourth anniversary from the date of grant, or August 14, 2028, subject to the Reporting Person's continued service as of the applicable vesting date;

(continued from footnote 2) (b) 65,000 RSUs, which shall vest as to one-half of the award on each of the first and second anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date and will be settled into Common Stock upon vesting;

(continued from footnote 3) (c) 175,000 RSUs, which will be settled into Common Stock upon a "Change In Control" of the Issuer, as defined in the Reporting Person's Employment Agreement, subject to the Reporting Person's continued service as of the applicable vesting date; and

(continued from footnote 4) (d) 116,613 shares of Common Stock owned by the Reporting Person.


Common Stock

Includes (a) 69,300 restricted stock units ("RSUs") granted on April 1, 2022 that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan") and (b) 8,519 shares of Common Stock owned by the reporting person.

/s/ Peter J. Mariani attorney-in-fact Jiny Kim


Common Stock

Includes: (i) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015;

(continued from footnote 2) (ii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 81,000 RSUs granted on April 2, 2024 and of which 40,500 remain unvested as of the date hereof; and

(continued from footnote 3) (iii) 429,668 shares of Common Stock owned by the Reporting Person.

/s/ Peter J. Mariani attorney-in-fact Vincent Capponi


Common Stock

Includes: (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and of which 30,500 remain unvested as of the date hereof; and

(continued from footnote 3) (iv) 197,525 shares of Common Stock owned by the reporting person.

/s/ Peter J. Mariani attorney-in-fact Efthymios Deliargyris


Common Stock

Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 3,300 RSUs granted on March 15, 2018, (b) 6,000 RSUs granted on February 24, 2017, (c) 5,000 RSUs granted on June 7, 2016, and (d) 55,000 RSUs granted on April 8, 2015 and (ii) 76,457 shares of Common Stock owned directly by the Reporting Person.

These shares are held in the Bernard Sobel Revocable Trust (the "Trust"), for which the Reporting Person is a trustee and a named beneficiary. Accordingly, the Reporting Person may be deemed the beneficial owner of the shares held in the Trust.

/s/ Peter J. Mariani attorney-in-fact Alan D. Sobel


Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest in one year from date of grant.

/s/Todd Smith, Chief Legal Officer, as attorney-in-fact


Class A

Class A

400,000 Class A Shares will vest as follows: 200,000 shares vest immediately on grant and the remainder vest in 22 equal monthly installments of 8,333 shares for each complete subsequent month of Continuous Service (as defined in the 2022 Equity Performance Plan) and 8,341 will vest on March 15, 2027.

500,000 Class A Shares are performance-based and vest upon the date on which either of the following occurs during the Exercisability Period (as defined in the Plan and option agreement: (x) a Class A Share has traded in the market on which the Class A Shares are listed for at least thirty (30) trading days at an average price of $20.00 or more, whether consecutive or non-consecutive, or (y) there are distributions of cash, stock or other property by the Company on the Class A Shares, at a value of $20.00 or more in the aggregate per Class A Share.

Exhibit 24 - Power of Attorney granted by Anthony DiGiandomenico


Common Stock, par value $0.0001 per share ("Common Stock")

Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates.


Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.


Reporting Persons' joint purchase of 6853 shares of Issuer's common stock on July 25, 2025 referenced in Table 1 was executed by the administrator of, and pursuant to, Issuer's dividend-reinvestment plan.

The object of this submission is to clarify the nature of the transaction reported by the Reporting Persons in Form 4 filed with the Commission on August 4, 2025; namely, that their acquisition of 6853 shares of Issuer's common stock on July 25, 2025 was attributable to stock purchases executed pursuant to the company's dividend-reinvestment plan.


By the Solomon Ascher Hochman 2019 Trust


The sale of shares was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person for the benefit of the reporting person's relatives on December 13, 2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.10 to $135.0942, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are held in trust for the benefit of the children of the reporting person for which the reporting person serves as trustee. The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.10 to $136.0974, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.10 to $137.095, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.10 to $137.87, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.50 to $139.53, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The exercises and/or sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.

These shares are held by a family trust for which the reporting person is co-trustee.

These shares are held in trust for the benefit of relatives of the reporting person for which the reporting person serves as co-trustee.  The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.

By: Isabelle Bertin-Bailly, Attorney-in-Fact For: Jayshree Ullal


Common Stock

The Reporting Person exercised options previously granted to him under the Company stock incentive plan, electing to pay the exercise price pursuant to the deemed net-stock exercise provision of such plan. As such, the Issuer withheld 6,993 shares at a fair market value of $9.76 per share being equal to the exercise price, such that the Reporting Person was issued 68,007 shares.

Granted pursuant to and in accordance with the Company's stock incentive plan.


Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest in one year from date of grant.


These shares are held directly by Fallen Leaf Revocable Trust for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of the shares except to the extent if his pecuniary interest therein.

These shares are held directly by Fallen Leaf LLC - Sub Fund No. 1 for which the reporting person serves as managing member. The reporting person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

These shares are held directly by a trust for the son of the reporting person, for which the reporting person serves as co-trustee.

These shares are held directly by a trust for the daughter of the reporting person, for which the reporting person serves as co-trustee.


Non-qualified Stock Option (Right to Buy)

Common Stock

As indicated by the checkbox above, this transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 9, 2025.

Shares held in the reporting person's name or in the Marc R. Benioff Revocable Trust.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $237.2777 to $238.2539 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $238.3722 to $239.2665 inclusive.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $239.3827 to $240.3577 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $240.3951 to $241.0147 inclusive.  The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $241.6334 to $242.5267 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $243.3128 to $244.2458 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $244.3646 to $244.9500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $245.5950 to $246.4334 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $247.0727 to $247.6148 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $248.2368 to $249.0366 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $249.3866 to $250.3192 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Weighted average price.  These shares were sold in multiple transactions at prices ranging from $251.5600 to $252.5229 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Shares held in the Marc Benioff Fund LLC (the "Fund").  Fund interests are held in the reporting person's name or in trust.

Option vests over four years at the rate of 25% on March 22, 2020, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.

/s/ Andrew Leeds, Attorney-in-Fact for Marc Benioff


Mr. Greathouse also serves as the Senior Vice President & Chief Investment Officer of CTO Realty Growth, Inc. ("CTO"). Mr. Greathouse disclaims beneficial ownership of all equity securities of the Issuer that are or may be beneficially owned by CTO or any of its affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Mr. Greathouse is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer that are or may be beneficially owned by CTO or any of its affiliates.

/s/ Daniel E. Smith, attorney-in-fact for Steven R. Greathouse


The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $14.17 to $14.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Mr. Albright also serves as the President, CEO and member of the Board of Directors of CTO Realty Growth, Inc. ("CTO"). Mr. Albright disclaims beneficial ownership of all equity securities of the Issuer that are or may be beneficially owned by CTO or any of its affiliates. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that Mr. Albright is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer that are or may be beneficially owned by CTO or any of its affiliates.

/s/ Daniel E. Smith, attorney-in-fact for John P. Albright


Donna Kalazdy, by power of attorney for Claire Fraser


The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.75 to $10.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.725 to $10.255 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $9.76 to $10.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.5 to $42.36 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.56 to $42.83 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

By: Patrick R. O'Neil, attorney-in-fact For: B. Lynne Parshall


Common Stock

Represents the weighted average of a range of sale prices from $88.50 to $88.70. The reporting person undertakes to provide to the Staff of the Securities and Exchange Commission, the Company, or any stockholder of the Company, upon request, full information regarding the number of shares sold at each separate price.

Received as employment compensation

/s/ Michael Peterson by Diane Gallagher, attorney-in-fact


Weighted average price. These shares were purchased in multiple transactions at prices ranging from $64.5650 to $64.9100 inclusive. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.

Beneficial ownership of the shares owned by Continental Grain Company ("CGC") listed above, and which Paul Fribourg may be deemed to beneficially own by virtue of his position as Chairman and Chief Executive Officer of CGC, is expressly disclaimed by Paul Fribourg, except to the extent of his pecuniary interest.

/s/ Chrystalla Potamitou,  attorney in fact


Common Stock

The stock option vests in a series of four (4) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the grant date, such that 100% of the stock option will be vested upon the first anniversary of the grant date.


The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 14, 2024.

This transaction was executed in multiple trades at prices ranging from $96.19 to $97.175. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from $97.20 to $97.24. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.


Employee Stock Option (Right to Purchase)

Common Stock

The stock option vests as follows: (i) 50% upon the first anniversary of the grant date, and (ii) the remaining 50% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date.


Common Stock


Common Stock

The stock options vest on December 31, 2026, subject to continued employment with the Company on the vesting date.


The sales reported were effected pursuant to the Rule 10b5-1 trading plan adopted by the reporting person on May 5, 2025.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.235 to $765.195 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares held of record by Christopher K. Cox, Trustee of The Christopher K. Cox Revocable Trust.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.25 to $766.055 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.31 to $767.13 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $767.50 to $768.49 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $768.50 to $769.44 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $769.505 to $770.14 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $770.58 to $770.88 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares held of record by Christopher K. Cox and Visra Vichit-Vadakan, Co-Trustees of The Cox-Vadakan Irrevocable Remainder Trust.

/s/ Erin Guldiken, attorney-in-fact for Christopher K. Cox


Non-Qualified Stock Option (right to buy)

Common Stock

Exercisable in a series of 4 equal and successive annual installments commencing 12 months following the date of grant.


The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2024.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.1700 to $166.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are owned directly by an estate planning trust ("Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.1700 to $167.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.1700 to $168.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.1700 to $169.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $169.1700 to $170.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $170.1700 to $171.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $171.1700 to $172.1600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.1700 to $173.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $173.1700 to $174.1550, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $174.2900 to $175.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are owned directly by an estate planning trust ("Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These shares are owned directly by an estate planning trust ("Trust 3"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.


Reflects shares underlying an annual award of restricted stock units ("RSUs") granted for the 2025-2026 board term under the issuer's non-employee director compensation program and the Navitas Semiconductor Corporation 2021 Equity Incentive Plan (the "Plan"). Each RSU represents the reporting person's right to receive one share of Class A Common Stock of the issuer following the vesting date in accordance with the Plan and subject to applicable issuer policies. The RSUs will vest in full immediately before the issuer's 2026 annual stockholders' meeting, subject to the reporting person's continued service as a director at that time, and provided such meeting is within 30 days of the first anniversary of the 2025 annual stockholders' meeting (otherwise the RSUs will vest one year after the grant date).

Reflects shares underlying RSUs granted to the reporting person in respect of the portion of the 2024-2025 board term during which the reporting person served as a director, and were fully vested upon grant.


The reporting person is a managing member of Live Oak Sponsor. The reporting person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.


The reporting person is managing director of Atlantic Bridge III LP. The reporting person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.


The reporting person is the sole manager of SiCPower, LLC and may be deemed to have indirect beneficial ownership of the reported securities held by SiCPower, LLC. The reporting person disclaims beneficial ownership of the reported securities, for purposes of Rule 16a-1(a)(2) under Section 16 of the Exchange Act.


The reporting person is a managing member of Live Oak Sponsor. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.


By Jain Foundation Inc. (Non-Profit Corporation)

Class B Common Stock

Class B Common Stock

Class B Common Stock

Class B Common Stock

2,000 shares of Class B Common Stock were sold at an average price of $464.725965 per share, with a range of $464.41 to $464.96 per share.

Each share of Class A Common Stock is convertible at any time at the option of the holder into 1,500 shares of Class B Common Stock.

Family trusts established by the Reporting Person's spouse for the benefit of the Reporting Person's descendants own 17 shares of Class A Common Stock.

Family trusts established by the Reporting Person for the benefit of the Reporting Person's descendants own 38 shares of Class A Common Stock.

The non-profit corporation Jain Foundation, Inc. owns 50 shares of Class A Common Stock.


Reflects award of vested RSUs in consideration for service on the board of directors.

Shares are held by Technology Impact Fund, L.P., of which the reporting person is managing director. The reporting person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Shares are held by Capricorn-Libra Investment Group, LP, of which the reporting person is managing director. The reporting person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.


These shares were sold in multiple transactions at prices ranging from $106.79 to $107.79 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares were sold in multiple transactions at prices ranging from $107.82 to $108.82 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares were sold in multiple transactions at prices ranging from $108.83 to $109.83 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares were sold in multiple transactions at prices ranging from $109.84 to $110.84 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares were sold in multiple transactions at prices ranging from $110.92 to $111.84 per share, inclusive. The holder undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These shares are owned directly by the Perisich Family Trust dated July 11, 2007 and indirectly by John M. Perisich, as trustee of the trust. Mr. Perisich is Chief Legal and Administrative Officer of Primoris.


Common Stock

Common Stock

Common Stock

Common Stock

Includes shares acquired pursuant to the Company's Employee Stock Purchase Plan.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.76 to $28.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.05 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.76 to $28.19 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These options were granted on November 5, 2021 and become eligible to vest and become exercisable in equal 25% increments, each upon the later of the occurrence of the first four anniversaries of the grant date, respectively, and the attainment of the closing price of the Company's common stock at or above, for each respective 25% increment, $19.66, $24.66, $29.66, and $34.66, for twenty consecutive trading days, subject to continued employment through such vesting date.

These options were granted on November 5, 2021 and vest and become exercisable in equal installments on each of the first four anniversaries of the grant date, subject to continued employment through such vesting date.


Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Not applicable.

Represents shares held by trust for the benefit of Ms. Niemann's family members, of which trusts Ms. Niemann's spouse serves as trustee.

Represents shares held by trusts for the benefit of Ms. Niemann's family members, of which trusts Ms. Niemann serves as trustee.

Represents shares held by a trust for the benefit of Ms. Niemann and her family, of which trust Ms. Niemann serves as co-trustee.

Represents shares held by CRASTECOM B Limited Partnership, of which Ms. Niemann is the managing general partner.  Ms. Niemann disclaims beneficial ownership of the shares of Class B Common Stock held by CRASTECOM except to the extent of her pecuniary interest therein.

Represents shares held by PILACON Limited Partnership, of which Ms. Niemann is the managing partner.  Ms. Niemann disclaims beneficial ownership of the shares of Class A Common Stock held by PILACON except to the extent of her pecuniary interest therein.

Shares of Class B Common Stock are convertible into shares of Class A Common Stock on a 1-for-1 basis.

Immediately convertible.


Class A Common Stock

Class A Common Stock

Not applicable.

Represents shares held by a trust for the benefit of Mr. Pew for which Mr. Pew serves as co-trustee.

Immediately convertible.


Common Stock

Common Stock

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.76 to $28.53 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

These options were granted on March 4, 2021 and become eligible to vest and become exercisable in equal 25% increments, each upon the later of the occurrence of the first four anniversaries of the grant date, respectively, and the attainment of the closing price of the Company's common stock at or above, for each respective 25% increment, $18.81, $23.81, $28.81, and $33.81, for twenty consecutive trading days, subject to continued employment through such vesting date.

These options were granted on March 4, 2021 and vested and became exercisable in equal installments on each of the first four anniversaries of the grant date, and were subject to continued employment through such vesting date.


Common Stock

Common Stock

These restricted stock units vest in four equal annual installments beginning on August 6, 2026 and upon vesting, will each be settled by delivery of one share of common stock, an equivalent amount of cash, or a combination thereof.

These stock options vest in four equal annual installments beginning on August 6, 2026.

Title: Senior Vice President PST Segment, Demand Generation and Execution


Common Stock

Common Stock

Title: Senior Vice President, General Counsel, Chief Compliance Officer and Secretary


Common Stock

These restricted stock units vest on August 6, 2026 and upon vesting, will each be settled by delivery of one share of common stock, an equivalent amount of cash, or a combination thereof.


Common Stock


Common Stock, par value $0.0001 per share


/s/ Anthony M. Robinson, for Paul J. Krump, per Power of Attorney


Common Stock

Includes shares issued pursuant to the dividend reinvestment plan.

This Non-qualified Stock Option becomes exercisable in 1 equal annual installments beginning on 4/29/2025.


Pre - Funded Common Stock Purchase Warrant

Common Stock

Exercise subject to the latter of the (i) effectiveness of articles of amendment to the Company's amended and restated articles of incorporation to increase authorized shares to 1,000,000,000 and (ii) 21st day following final information statement for Nasdaq Rule 5635(d) approval (the "Initial Exercise Date").

No expiration until exercised in full; exercise price pre-funded


The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $24.00 to $24.93, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $24.4046 to $24.9775, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.


The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2025.

Represents weighted average sales price. The shares were sold at prices ranging from $176.280 to $177.260. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $177.280 to $178.275. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $178.280 to $179.270. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $179.280 to $179.850. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $178.815 to $179.810. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $179.820 to $180.815. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $180.820 to $181.810. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $181.820 to $182.810. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $182.820 to $183.780. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $180.430 to $181.390. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $181.430 to $182.425. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Represents weighted average sales price. The shares were sold at prices ranging from $182.430 to $183.280. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

The shares are held by Jen-Hsun Huang and Lori Huang, as co-trustees of the Jen-Hsun & Lori Huang Living Trust, u/a/d May 1, 1995 (the "Trust").

The shares are held by J. and L. Huang Investments, L.P., of which the Trust is the general partner.

The shares are held by The Huang 2012 Irrevocable Trust, of which the Reporting Person is a trustee.

The shares are held by The Huang Irrevocable Remainder Trust u/a/d February 19, 2016, of which the Reporting Person is a trustee.

The shares are held by The Lori Lynn Huang 2016 Annuity Trust II Agreement.

The shares are held by The Jen-Hsun Huang 2016 Annuity Trust II Agreement.

The shares are held by TARG S LLC, of which the Trust is the sole member.

The shares are held by TARG M LLC, of which the Trust is the sole member.

/s/ Rebecca Peters, Attorney-in-Fact for Jen-Hsun Huang


8.00% Cumulative Preferred Stock, Series A, $25.00 par value

Pre-Funded Common Stock Purchase Warrant

Common Stock

Common Stock

The holding companies managed by Fundamental Global GP, LLC ("FGGP"), including FG Financial Holdings LLC ("FGFH") and Fundamental Global Holdings LLC ("FGHL"), beneficially own in the aggregate 78,131 shares of the Issuer's preferred stock, 329,965 shares of the Issuer's common stock, and 300,000 of the Issuer's pre-funded common stock purchase warrants. FGGP may be deemed to be a beneficial owner of the securities disclosed as directly owned by FGFH and FGHL. Due to their positions with FGGP and affiliated entities, Messrs. D. Kyle Cerminara and Joseph H. Moglia may be deemed to be beneficial owners of the securities disclosed as directly owned by FGFH and FGHL. Each Reporting Person disclaims beneficial ownership of the shares of the Issuer's Preferred Stock and common stock beneficially owned by FGGP except to the extent of his or its pecuniary interest therein.

Exercise subject to the latter of the (i) effectiveness of articles of amendment to the Company's amended and restated articles of incorporation to increase authorized shares to 1,000,000,000 and (ii) 21st day following final information statement for Nasdaq Rule 5635(d) approval (the "Initial Exercise Date").

No expiration until exercised in full; exercise price pre-funded.


Adoption date of referenced 10b5-1(c) plan is: 03-10-2025

The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $93.03 to $94.00. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.


Common Stock

Common Stock

Common Stock

Expires ten years from Initial Exercise Date. Exercise limited to 50% of warrant shares until Company purchases $150 million in Ethereum tokens.

FG Financial Holdings LLC ("FGFH") beneficially owns in the aggregate 329,965 shares of FG Common Stock. Fundamental Global GP LLC ("FGGP"), which is an affiliate of FGFH, may be deemed to be a beneficial owner of the securities disclosed as directly owned by FGFH. Due to Mr. Cerminara's position with FGGP and affiliated entities, Mr. Cerminara may be deemed to be beneficial owner of the securities disclosed as directly owned by FGFH. Mr. Cerminara disclaims beneficial ownership of the shares of FG Common Stock beneficially owned by FGFH and FGGP except to the extent of his pecuniary interest therein.


These shares were sold in multiple transactions at prices ranging from $415.18 - $415.82, inclusive. The reporting person, upon request, will submit to the Securities and Exchange Commission the number of shares sold at each separate price within the range set forth in this footnote.

Reflects tax withholding and performance share achievement on vesting.


Common Stock

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 11, 2024.

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.54 to $45.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

1/48th of the total number of shares subject to the option shall vest on each monthly anniversary of January 1, 2024 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.

/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact


Common Stock

Common Stock

All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024.

All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person.


Common Stock

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024.

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This option is fully vested and exercisable as of the date of this Report.


Common Stock

Common Stock

Common Stock

Common Stock

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.15 to $46.44. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

This option was granted on February 14, 2022 and vests in equal installments of 5,652 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on February 14, 2026.

This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.

This option was granted on January 20, 2023 and vests in equal installments of 3,083 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2027.

This option was granted on January 20, 2024 and vests in equal installments of 2,208 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on January 20, 2028.


Common Stock

These shares were sold in multiple transactions at prices ranging from $418.30 - $419.43, inclusive. The reporting person, upon request, will submit to the Securities and Exchange Commission the number of shares sold at each separate price within the range set forth in this footnote.


The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions on August 7, 2025 at prices ranging from $36.9400 to $37.3050, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

/s/ Justin D. Mogford, attorney-in-fact for Stuart Stavley


Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary Shares

Ordinary shares withheld  to cover exercise price and tax withholdings.

The price reported is the weighted average sale price. The sale prices ranged from $471.39 to $474.62. Upon request of the SEC Staff, Linde plc or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

The Restricted Stock Unit ("RSU") shall vest in full and payout in Ordinary Shares on a one-for-one basis one year after the March 7, 2025 date of grant, provided that the awardee serves on the Linde plc Board of Directors continuously through the vesting date, except under certain circumstances in which a pro-rata payout may be made.

Restricted Stock Units that will vest in full and payout on or about March 8, 2024 in Linde plc Ordinary Shares on a one-for-one basis.

Restricted Stock Units that have vested in full but whose payout has been deferred to a future date.

Restricted Stock Units granted March 20, 2019, that have vested in full but whose payout has been deferred to a future date.

Restricted Stock Units granted February 27, 2018, that have vested in full but whose payout has been deferred to a future date.

Restricted Stock Unit award granted February 28, 2017, that has vested in full but whose payout has been deferred to a future date.

Restricted Stock Units granted February 28, 2017, that have vested in full but whose payout has been deferred to a future date.

Restricted Stock Unit award granted February 23, 2016, that has vested in full but whose payout has been deferred to a future date.

This option vests over three years in three consecutive equal annual installments beginning on March 8, 2022.

This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.

This option vests over three years in three consecutive equal annual installments beginning on March 20, 2020.

This option vests over three years in three consecutive equal annual installments beginning on February 27, 2019.

This option vests over three years in three consecutive equal annual installments beginning on February 28, 2018.

Conversion to Linde plc Ordinary Shares is on a 1-for-1 basis

Deferred Stock Units acquired under the Linde Compensation Deferral Plan that will payout in Linde plc Ordinary Shares on a one-for-one basis in accordance with the Deferral Plan.


The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on August 7, 2025 at prices ranging from $37.48 to $37.56, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

/s/ Justin D. Mogford, Attorney-in-Fact for Jennifer D. Whalen


The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions on August 7, 2025 at prices ranging from $37.0000 to $37.4919, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions on August 7, 2025 at prices ranging from $38.3100 to $38.4234, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

/s/ Justin D. Mogford, Attorney-in-Fact for Robert Manzo


Glow NS Holdings, LLC is controlled by Glow NS Intermediate Holdings, LLC, its sole member. Glow B Holdings, LLC and Glow NS Intermediate Holdings LLC are controlled by Glow Aggregator, LLC as each entity's sole member. Glow Aggregator, LLC is controlled by AE Industrial Partners Fund II, L.P. as managing member. AE Industrial Partners Fund II, L.P. is controlled by AE Industrial Partners Fund II GP, LP ("AE Fund II GP"), its general partner. Glow C Holdings, LLC, and Glow D Holdings, LLC are controlled by AE Industrial Partners Fund III, LP as managing member. AE Co-Investment Partners Fund III-F, LP and AE Industrial Partners Fund III, LP are controlled by AE Industrial Partners Fund III GP, LP ("AE Fund III GP"), as each entity's general partner. AE Industrial Partners Structured Solutions I, LP is controlled by AE Industrial Partners Structured Solutions I GP, LP ("AE Solutions GP"), its general partner.

(Continued from footnote 1) AE Fund II GP, AE Fund III GP, and AE Solutions GP are each managed by each entity's respective general partner, AeroEquity GP, LLC. AeroEquity GP, LLC is controlled by its managing members, Michael Greene and David Rowe. Messrs. Greene and Rowe make all voting and investment decisions with respect to the securities held by AE Industrial Partners. Each of the entities and individuals named above disclaims beneficial ownership of the securities held by AE Industrial Partners, except to the extent of its pecuniary interest therein.

Held by David Rowe.

Held by Glow B Holdings, LLC.

Held by Glow C Holdings, LLC.

Held by Glow D Holdings, LLC.

Held by Glow NS Holdings, LLC.

Held by AE Co-Investment Partners Fund III-F, LP.


Common Stock

The option represents a right to purchase a total of 79,456 shares of the Issuer's common stock, which shall vest as to one-third of the shares underlying the option on each of the first, second and third anniversaries of the grant date of the award, subject to the Reporting Person's continued service as a director on each such vesting date.


Common Stock


Common Stock

On August 6, 2025 (the "Grant Date"), the Reporting Person was granted an option to purchase 1,790,000 shares of the Issuer's common stock pursuant to the Issuer's 2021 Equity Incentive Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.


A deferred share unit ("DSU") award was granted on August 6th, 2025 where 5,419 are scheduled to vest on June 15, 2026. The DSU award is subject to continued service through the vesting date.

Each DSU represents the right to receive one share of the Company's Class A Common Stock.

Includes 62,886 shares of Class A common stock to be delivered in settlement of DSU awards. The DSU awards, in each case, are subject to continued service through the applicable vesting date.

The shares of Class A common stock reported in this transaction represent a bona-fide charitable gift to a Donor Advised Fund.

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.20 to $28.32 per share. The holder undertakes to provide to the
issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within
the range set forth in this footnote.

/s/ Francesca Don Angelo, Attorney-in-Fact for Richard Tavoso